The effect of a single nucleotide polymorphismof the CYP4F2 gene on blood pressure and 20-hydroxyeicosatetraenoic acidexcretion after weight loss

Journal of Hypertension

Volumn 32, Issue 7, 2014, Pages 1495-1502

  Ward, Natalie C ^a   Croft, Kevin D ^a   Puddey, Ian B ^a   Phillips, Michael ^c   Van Bockxmeer, Frank ^b   Beilin, Lawrence J ^a   Barden, Anne E ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b School of Surgery and Pathology   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

20 hydroxyeicosatetraenoic acid; CYP4F2 V433M; Cytochrome P450; Pulse pressure; Weight loss; Weight stabilisation

Indexed keywords

20 HYDROXYICOSATETRAENOIC ACID; CYP4F2 ENZYME; CYTOCHROME P450; CYTOCHROME P450 4A11; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; 20-HYDROXY-5,8,11,14-EICOSATETRAENOIC ACID; CYP4A11 PROTEIN, HUMAN; CYP4F2 PROTEIN, HUMAN; GLUCOSE BLOOD LEVEL; HYDROXYICOSATETRAENOIC ACID; LIPID;

ADULT; AGED; ANTHROPOMETRY; ARTERIAL STIFFNESS; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE MONITORING; CLINICAL ARTICLE; CONTROLLED STUDY; DIET RESTRICTION; FATTY ACID BLOOD LEVEL; FEMALE; GENETIC VARIABILITY; HEART RATE; HUMAN; MALE; MASS FRAGMENTOGRAPHY; PRIORITY JOURNAL; PULSE PRESSURE; SINGLE NUCLEOTIDE POLYMORPHISM; SODIUM EXCRETION; SODIUM INTAKE; URINARY EXCRETION; WEIGHT REDUCTION; BLOOD; CONTROLLED CLINICAL TRIAL; GENETIC ASSOCIATION; GENETICS; GLUCOSE BLOOD LEVEL; METABOLISM; MIDDLE AGED; OBESITY; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; URINE; YOUNG ADULT;

ADULT; AGED; BLOOD GLUCOSE; BLOOD PRESSURE; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; GENETIC ASSOCIATION STUDIES; HEART RATE; HUMANS; HYDROXYEICOSATETRAENOIC ACIDS; LIPIDS; MALE; MIDDLE AGED; OVERWEIGHT; POLYMORPHISM, SINGLE NUCLEOTIDE; VASCULAR STIFFNESS; WEIGHT LOSS; YOUNG ADULT;

EID: 84903828184     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0000000000000208     Document Type: Article

References (27)

1. Roman RJ. P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol Rev 2002; 82:131-185
2. Hoagland KM, Flasch AK, Roman RJ. Inhibitors of 20-HETE formation promote salt-sensitive hypertension in rats. Hypertension 2003; 42:669-673
3. Stec DE, Roman RJ, Flasch A, Rieder MJ. Functional polymorphism in human CYP4F2 decreases 20-HETE production. Physiol Genomics 2007; 30:74-81
4. Gainer JV, Bellamine A, Dawson EP, Womble KE, Grant SW, Wang Y, et al. Functional variant of CYP4A11 20-hydroxyeicosatetraenoic acid synthase is associated with essential hypertension. Circulation 2005; 111:63-69
5. Ward NC, Tsai IJ, Barden A, van Bockxmeer FM, Puddey IB, Hodgson JM, et al. A single nucleotide polymorphism in the CYP4F2 but not CYP4A11 gene is associated with increased 20-HETE excretion and blood pressure. Hypertension 2008; 51:1393-1398
6. Tsai IJ, Croft KD, Mori TA, Falck JR, Beilin LJ, Puddey IB, et al. 20-HETE and F2-isoprostanes in the metabolic syndrome: the effect of weight reduction. Free Radic Biol Med 2009; 46:263-270
7. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Executive summary of the third report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285:2486-2497
8. Rivera J, Ward N, Hodgson J, Puddey IB, Falck JR, Croft KD. Measurement of 20-hydroxyeicosatetraenoic acid in human urine by gas chromatography-mass spectrometry. Clin Chem 2004; 50:224-226
9. Fava C, Montagnana M, Almgren P, Rosberg L, Lippi G, Hedblad B, et al. The V433M variant of the CYP4F2 is associated with ischemic stroke in male swedes beyond its effect on blood pressure. Hypertension 2008; 52:373-380
10. Straznicky NE, Grima MT, Eikelis N, Nestel PJ, Dawood T, Schlaich MP, et al. The effects of weight loss versus weight loss maintenance on sympathetic nervous system activity and metabolic syndrome components. J Clin Endocrinol Metab 2011; 96:E503-E508
11. Domanski MJ, Mitchell GF, Norman JE, Exner DV, Pitt B, Pfeffer MA. Independent prognostic information provided by sphygmomanometrically determined pulse pressure and mean arterial pressure in patients with left ventricular dysfunction. J Am Coll Cardiol 1999; 33:951-958
12. Zheng L, Sun Z, Li J, Zhang R, Zhang X, Liu S, et al. Pulse pressure and mean arterial pressure in relation to ischemic stroke among patients with uncontrolled hypertension in rural areas of China. Stroke 2008; 39:1932-1937
13. Hu BC, Li Y, Li FH, Zhang Y, Sheng CS, Fan HQ, et al. Peripheral and central augmentation indexes in relation to the CYP4F2 polymorphisms in Chinese. J Hypertens 2011; 29:501-508
14. Dengel DR, Kelly AS, Olson TP, Kaiser DR, Dengel JL, Bank AJ. Effects of weight loss on insulin sensitivity and arterial stiffness in overweight adults. Metab Clin Exp 2006; 55:907-911
15. Goldberg Y, Boaz M, Matas Z, Goldberg I, Shargorodsky M. Weight loss induced by nutritional and exercise intervention decreases arterial stiffness in obese subjects. Clin Nutr 2009; 28:21-25
16. Dengo AL, Dennis EA, Orr JS, Marinik EL, Ehrlich E, Davy BM, et al. Arterial destiffening with weight loss in overweight and obese middleaged and older adults. Hypertension 2010; 55:855-861
17. Weisbrod RM, Shiang T, Al Sayah L, Fry JL, Bajpai S, Reinhart-King CA, et al. Arterial stiffening precedes systolic hypertension in diet-induced obesity. Hypertension 2013; 62:1105-1110
18. Ward NC, Rivera J, Hodgson J, Puddey IB, Beilin LJ, Falck JR, et al. Urinary 20-hydroxyeicosatetraenoic acid is associated with endothelial dysfunction in humans. Circulation 2004; 110:438-443
19. Lasker JM, Chen WB, Wolf I, Bloswick BP, Wilson PD, Powell PK. Formation of 20-hydroxyeicosatetraenoic acid, a vasoactive and natriuretic eicosanoid, in human kidney: role of CYP4F2 and CYP4A11. J Biol Chem 2000; 275:4118-4126
20. Schwartzman ML, Martasek P, Rios AR, Levere RD, Solangi K, Goodman AI, et al. Cytochrome-P450-dependent arachidonic-acid metabolism in human-kidney. Kidney Int 1990; 37:94-99
21. Prakash C, Zhang JY, Falck JR, Chauhan K, Blair IA. 20- hydroxyeicosatetraenoic acid is excreted as a glucuronide conjugate in human urine. Biochem Bioph Res Co 1992; 185:728-733
22. Imig JD, Zou AP, Stec DE, Harder DR, Falck JR, Roman RJ. Formation and actions of 20-hydroxyeicosatetraenoic acid in rat renal arterioles. Am J Physiol 1996; 270 (1 Pt 2):R217-R227
23. Schwartzman M, Ferreri NR, Carroll MA, Songumize E, McGiff JC. Renal Cytochrome-P450-related arachidonate metabolite inhibits (Na+ + K+)atpase. Nature 1985; 314:620-622
24. Croft KD, McGiff JC, Sanchez-Mendoza A, Carroll MA. Angiotensin II releases 20-HETE from rat renal microvessels. Am J Physiol Renal Physiol 2000; 279:F544-F551
25. Kalyankrishna S, Malik KU. Norepinephrine-induced stimulation of p38 mitogen-activated protein kinase is mediated by arachidonic acid metabolites generated by activation of cytosolic phospholipase A(2) in vascular smooth muscle cells. J Pharmacol Exp Ther 2003; 304:761- 772
26. Cheng J, Ou JS, Singh H, Falck JR, Narsimhaswamy D, Pritchard KA, et al. 20-hydroxyeicosatetraenoic acid causes endothelial dysfunction via eNOS uncoupling. Am J Physiol-Heart C 2008; 294:H1018-H1026
27. Fava C, Montagnana M, Danese E, Sjogren M, Almgren P, Guidi GC, et al. The functional variant V433M of the CYP4F2 and the metabolic syndrome in Swedes. Prostag Oth Lipid M 2012; 98:31-36.